The capacity of a polypeptide chain to engage in an amyloid formation process and cause a conformational disease is contained in its sequence. Some of the sequences undergoing fibrillation contain critical methionine (Met) residues which in vivo can be synthetically substituted by selenomethionine (SeM) and alter their properties.
Using peptide synthesis, biophysical techniques and cell viability determinations we have studied the effect of the substitution of methionine (Met) by selenomethionine (SeM) on the fibrillogenesis and toxic properties of Aβ40 and HuPrP(106–140). We have found that the effects display site-specificity and vary from inhibition of fibrillation and decreased toxicity ([SeM35]Aβ40, [SeM129]HuPrP(106–140) and [SeM134]HuPrP(106–140)), retarded assembly, modulation of polymer shape and retention of toxicity ([SeM112]HuPrP(106–140) to absence of effects ([SeM109]HuPrP(106–140)).
This work provides direct evidence that the substitution of Met by SeM in proamyloid sequences has a major impact on their self-assembly and toxic properties, suggesting that the SeM pool can play a major role in dictating the allowance and efficiency of a polypeptide chain to undergo toxic polymerization.
Citation: Martínez J, Lisa S, Sánchez R, Kowalczyk W, Zurita E, Teixidó M, et al. (2011) Selenomethionine Incorporation into Amyloid Sequences Regulates Fibrillogenesis and Toxicity. PLoS ONE 6(11): e27999. https://doi.org/10.1371/journal.pone.0027999
Editor: Andrew Francis Hill, University of Melbourne, Australia
Received: July 13, 2011; Accepted: October 30, 2011; Published: November 22, 2011
Copyright: © 2011 Martínez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by gra'ts BFU2009-07975 (MG), BIO2008-04487-CO3-02 (DA) and BIO2008-00799 (EG) from the Spanish Ministry of Science and Innovation, from the Fundación Cien-Fundación Reina Sofia, and from Generalitat de Catalunya (XRB and Grups Consolidats). Wioleta Kowalczyk is supported by a Juan de la Cierva fellowship from the Spanish Ministry of Science and Innovation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Protein conformational diseases share the occurrence of a basic misfolding event that leads to the accumulation of proteins or fragments thereof as distinct oligomeric self-assemblies with gained toxic functions –. Among the various assemblies, amyloids refer to highly ordered cross β-sheet fibrillar aggregates resulting from tight interfacing of complementary β-sheets –. Despite the regulation by covalent modifications such as proteolytic cleavage, glycosilation and oxidation, among others, the gross information dictating the capacity of a polypeptide chain to form an amyloid is contained in its sequence , , . Therefore, deciphering the rules for modulating these sequences, their conformation and their self-assembly preferences is fundamental for the design of preventive therapies.
Among the different strategies for modifying protein sequences, the replacement of Met residues by SeM is unique in that it occurs in the absence of changes at the nucleic acid level , . Like Met, SeM is an essential amino acid for humans and its availability is strictly related to diet , , . SeM incorporates non-specifically into proteins in competition with Met . As an organic part of the Se pool, the reduction of its levels has been correlated with an enhanced risk of aging disorders –. In principle, Met substitution by SeM is regarded as a structurally inert change that is exploited for the phasing of macromolecular structures in X-ray crystallography . However, some reports indicate changes in the stability of proteins due to the increased hydrophobicity and distinct oxidation susceptibility of SeM compared to Met –. Thus, changes in the Met/SeM ratio can be considered as a source of transient, metabolic or non-coded mutations and their effect on proteins may vary as a function of residue location.
Of the various amyloid-forming sequences, the amyloid β peptides (Aβ40 and Aβ42) and the PrP(106–140) region are essential components of protein deposits in degenerative dementias and share the presence of regulatory Met residues –. Aβ40 and Aβ42, produced by sequential proteolytic cleavage of the amyloid β-protein precursor (APP) by β- and γ-secretase, accumulate both as extracellular amyloid deposits and synaptic oligomers in Alzheimer disease (AD) . In both Aβ peptides, Met35, through the oxidation of its side chain, modulates the oligomerization kinetics, the shape of the final polymer (oligomer vs amyloid fibril) and the neurotoxic function , –. In prion protein amyloidoses such as Gerstmann-Straussler-Scheinker syndrome and cerebral amyloid angiopathy, fragments overlapping the 106–140 region of the cellular prion protein (PrPC) form the specific amyloid deposits , , . This sequence (HuPrP) contains four Met residues (Met109, Met112, Met129, Met134) flanking either side of the palindromic AGAAAAGA region essential for assembly . Of those, Met109 and Met112 are not conserved in mammalian PrP sequences and their mutation to Val does not impede fibrillation while it regulates the processing at the α-cleavage site , , . On the other hand Met129 and Met132 are polymorphic positions in human and deer, respectively, and their substitution by Val or Leu regulates the disease phenotype and the ability to recognize and amplify exogenous prions , , , , .
To establish the role of Se intake as related to its specific incorporation as SeM into amyloid forming sequences, we have synthesized Aβ40 and HuPrP(106–140) sequences containing SeM as a replacement for Met. In contrast to the single Met35 substitution in Aβ40, the presence of four methionines in HuPrP(106–140) allows to investigate the role of the replacement site on fibril formation. Herein we show that the substitution of Met by SeM in Aβ40 and HuPrP(106–140) regulates both amyloid formation and toxicity. For HuPrP(106–140), the inhibitory effect displays site-specificity, with the activity varying from inhibition of fibrillation and decrease in toxicity ([SeM35]Aβ40 and [SeM129]HuPrP(106–140)) to accelerated fibrillation and modulation of the polymer shape with retention of toxicity ([SeM109]HuPrP(106–140) and [SeM112]HuPrP(106–140)).
SeM incorporation to amyloid sequences
Figure 1 shows the sequences of Aβ40 and HuPrP(106–140), both with amyloid-forming capacity and with one or more Met residues with relevant roles , . The single methionine (Met35) in Aβ40 allowed an unambiguous SeM replacement, while the four (Met109, Met112, Met129, Met134) in HuPrP(106–140) required a more extensive investigation of the site-specificity of SeM replacement. Hence, the wt HuPrP(106–140) sequence with four SeM residues (all-M), a non-oxidizable variant sequence (all-V) with all four Met residues mutated to Val, plus four analogs with single SeM replacements at either position 109, 112, 129 or 134, and Val at the other positions, were prepared. While all seven peptide sequences are of a size generally regarded as viable for solid phase synthesis methodologies, their well-known tendency to aggregate clearly placed them in the “synthetically difficult” category . This fact, plus the need for cost-effective handling of the high-priced Fmoc-SeM building block, called for highly optimized, state of the art synthetic strategies. Thus, for [SeM35]Aβ40, the O-acyl isopeptide approach  to difficult sequences was applied, whereby a soluble precursor, 26-O-isoacyl-[SeM35]Aβ(1–40), was prepared and purified to near-homogeneity, then incubated at pH 7.4 to give the target peptide in precipitate form. For its part, [SeM109,112,129,134]HuPrP(106–140) (all-M), its all-Val counterpart and the four site-specifically SeM-substituted analogs were efficiently assembled by microwave-assisted solid phase synthesis on ChemMatrix®, a resin proven successful in preventing aggregation during the synthesis of large, complex peptides . Peptides were successfully purified from the crude material and their identity and homogeneity confirmed by mass spectrometry . Full details on the synthesis, purification and analytical documentation of all peptides are given in the Supporting Information S1 file.
SeM35 impedes Aβ40 fibrillation
To investigate the ability of SeM to modify the aggregation properties of Aβ40 we set up a ThT binding kinetics assay. To this end, either wt Aβ40 (Met35) or [SeM35]Aβ40 were incubated at 20–40 µM concentration in PBS in the presence of 15 µM ThT and the increase in fluorescence emission as consequence of its binding to cross β-sheets was monitored (see methods). Figure 2A shows that wt Aβ40 at 20 µM and 30°C provokes a time-dependent increase in ThT fluorescence compatible with the known fibrillation process . Importantly, the kinetic trace was reproducible in independent experiments with different batches, with an average lag-phase of 13±2 h. In contrast, incubation of [SeM35]Aβ40 under similar conditions did not cause any detectable change in ThT fluorescence. Increasing [SeM35]Aβ40 concentration up to 200 µM and the incubation time up to 1 week did not provoke any significant or additional change. These results suggest that the substitution of Met by SeM has a clear deleterious impact on amyloid formation.
(A) Fibrillation kinetics followed by ThT binding. The displayed curves were obtained by continuous incubation of 20 µM peptide solutions in PBS containing 15 µM ThT at 30°C run in triplicate, and represent the average of three independent experiments. (B) Representative silver-stained SDS-PAGE gel of [Met35]Aβ40 and [SeM35]Aβ40 before (pre) and after 80 h (post) of incubation under aggregating conditions. Arrows indicate the distinct oligomers. (C) AFM topography imaging of the aggregation reaction products of [Met35]Aβ40 and [SeM35]Aβ40 after 80 h of incubation. Inserts displayed the magnification of a representative area of each case.
To confirm the previous findings we analyzed the reaction products by Atomic Force Microscopy (AFM). Figure 2C shows that, as expected from the ThT fluorescence readings, Aβ40 assembles into long (>200 nm length) and thin (7 nm height and about 2×40 nm diameter) fibrils that appear decorated by globular particles of about 4 nm in height and 40–80 nm in diameter [Figure 2C insert]. In contrast, [SeM35]Aβ40 uniquely yields globular aggregates characterized by 3.5–7 nm height and 35 nm average diameter, corroborating the impairment of the fibrillation process. On the other hand, [SeM35]Aβ40 aggregates yielded electrophoretic patterns different from those of toxic Aβ40 oligomers [Figure 2B] .
SeM effect on fibrillation displays site-specificity
To ascertain whether the previous findings are uniquely related to the Aβ40 sequence and the essential role played by Met35, or can take place also in other sequences, we analyzed the effect of this substitution on the fibrillation properties of HuPrP(106–140). In this case, given the presence of four Met residues and the possible interference of undesired oxidations in long time incubations, we investigated a non-oxidizable version (all-V, all four Met replaced by Val), as well as single SeM replacements with Val at the other positions [Figure 1].
Figure 3A shows that, at 30°C, 20 µM concentration in PBS and with mild orbital shaking, both all-M and all-V HuPrP(106–140) undergo fibrillation, though with notable kinetic differences. Thus, all-M HuPrP(106–140) exhibits the kinetic profile of a highly cooperative process, characterized by an average lag time of 33.8±2.0 h and a final arbitrary ThT fluorescence intensity of 60±5, whereas fibrillation of the all-V variant is characterized by a lag-phase of about 16.4±2.0 h and a final ThT intensity reading of 40±4 [Figures 3A and 3B]. These differences found here for the (106–140) sequence regions agree with previous findings reporting the faster polymerization of [Val129]PrP compared to [Met129]PrP and the higher propensity of [Met129]PrP(109–135) over its Val129 variant to form β-sheet stabilized fibers , . Placing SeM at position 109 slightly reduces both the lag phase and the final ThT intensity of the fibrillation kinetics. However, the absence of a clear statistical significance in these changes suggests that SeM109 behaves as an all-Val variant. On the contrary, placing SeM at position 112 significantly increases the lag time to 19.7±1.2 h with no effects in the maximum ThT intensity. Surprisingly, the introduction of SeM at position 129 drastically impairs the fibrillation process. Prolonged incubations (up to 1 week) yielded ThT intensity increases below 2.5 with averaged lag phases of >72 h. Along similar lines but to a lesser extent, placing SeM at position 134 allowed a slight fibrillation process featured by a final ThT intensity of 8 and a lag time of 31.5±2.0 h.
(A) Representative fibrillation kinetics of HuPrP(106–140) sequences followed by ThT binding. The color code of the traces is depicted as an insert in each panel. The displayed curves were obtained by continuous incubation of 20 µM peptide solutions in PBS containing 15 µM ThT at 30°C run in triplicate, and represent the average of three independent experiments. (B) Lag times of the fibrillation kinetics of HuPrP(106–140) and of its variants. Lag times were calculated independently from each curve and analyzed statistically using the Student's t-test tool provided by Origin 6 software: *, non-significant; **, P<0.05. (C) Phase images of the molecular species formed after 80 h incubation of HuPrP(106–140) sequences. The displayed fields for all-V, all-M, SeM109 and SeM112 sequences represent most frequent areas (9 out 10 analyzed 1 µm×1 µm regions). For SeM129 and SeM134 the displayed fields represent the minor hits (1 out of 20 analyzed 1 µm×1 µm regions).
To confirm these findings we analyzed by AFM the products of the aggregation reactions [Figure 3C]. In agreement with the ThT kinetics, the all-M, all-V, SeM109 and SeM112 versions of HuPrP(106–140) yielded fibrillar structures, of which those formed by SeM112 differed notably from the others by appearing as regular straight rods with a high homogeneity in length. On the contrary, the reaction product of the SeM129 analog yielded mainly amorphous aggregates with rarely the presence of fibrillar aggregates. The SeM134 peptide displayed an intermediate behaviour, showing few but detectable fibrillar assemblies. The aggregation profile was also studied by SDS-PAGE. Figure 4A shows that on aggregation all-M, all-V, SeM109 and SeM112 versions of PrP(106–140) yielded bands of SDS-resistant aggregated species, whereas SeM129 and SeM134 ran mainly as monomers.
(A) Typical aggregation pattern of HuPrP(106–140) and of its variants probed by silver-stained SDS-PAGE. Peptide aliquots (1 µg) before (pre) and after 80 h (post) of aggregation were separated in TGX-Precast BioRad gels and then silver stained. (B) Normalized ThT binding of the insoluble aggregates formed by HuPrP(106–140) peptides. Aggregated peptides were isolated as insoluble pellets of 30 min centrifugations at 15000 rpm, resuspended in PBS at 60 µM concentration. ThT binding of the resuspended aggregates was measured by fluorescence at 20 µM peptide and 15 µM ThT concentrations. (C) Far-UV CD spectral features of the insoluble aggregates formed by HuPrP(106–140) peptides. Insoluble pellets were prepared as in panel B in PBS and the spectra recorded at 60 µM. At least three separate experiments were performed to confirm these results.
Taken together these data indicate that, as for the case of Aβ40, SeM incorporation also impairs HuPrP(106–140) fibrillation, but in this case the inhibitory process is highly dependent on the replacement site, with position 129 and to a lesser extent 134 being essential in this respect.
SeM modulates fibril shape
As noted above, [SeM112]HuPrP(106–140) forms fibrillar aggregates that differ notably from those obtained from all-M, all-V and SeM109 peptides. To gain an insight on the basis of this polymorphism, the fibrils were isolated from the aggregation reactions by centrifugation and, after resuspension, were characterized for their ThT binding on fibril molar basis and by far-UV CD for comparison with previous reports . It must be noted that SeM129 and SeM134 peptides were not considered in this study given their failure to form fibrils with minimal efficiency.
Figure 4B shows that the fibrillar aggregates of all-M, all-V, SeM109 and SeM112 recovered by centrifugation from the aggregation reactions and resuspended to similar molar concentration yield similar ThT intensity, and the minor variations are not statistically significant. Figure 4C shows that the all-M, all-V and SeM109 peptides shared a common spectrum, featured by a double minimum at 208 and 220 nm suggesting an altered β-sheet structure. On the contrary, the spectrum of the SeM112 analog displayed the features of a pure β-sheet structure. The results thus support that, depending on its incorporation site, SeM can modulate the secondary structure and subsequently sculpture its self-assembly shape.
Interestingly, these distinct spectral features have been previously reported for the R- and S-fibrils formed by the full length PrP resulting from the aggregation using two different conditions . In fact the morphological and spectral features herein found for the aggregates formed by the SeM112 analog resemble those described for S-fibrils, which can be formed with the HaPrP but not with the MoPrP , . Similarly, the features of the fibrils formed by the all-M, all-V and SeM109 peptides resemble the properties described for the R-fibrils which can be formed by both HaPrP and MoPrP , . Among other sequence differences, HaPrP and MoPrP differ in the residue at position 112, Met in HaPrP and Val in MoPrP. Since Met though not Val can be metabolically replaced by SeM, it is tempting to speculate that the formation of S-fibrils could be dictated at least in part by the presence of chains containing SeM in position 112, which can uniquely occur with HaPrP, not with MoPrP.
SeM effects on fibrillation are unrelated to oxidation
As with Met, the SeM side chain can undergo oxidation to selenoxide and selenone, and if so could drastically modify the process of amyloid formation , –. To investigate whether the observed differences in fibrillation were related to SeM oxidation we analyzed by MALDI FT-ICR the peptides before and after the aggregation reaction. In all cases, m/z patterns of pre-aggregated and post-aggregated samples were superimposable and peaks reproduced the theoretical predicted charged masses [Figure 5, Supporting Information]. Importantly, no peaks at +16/+32 Da expected for the oxidized variants were detected [Figure 5]. Despite the non-quantitative nature of the mass spectrometry method, it plausible discards that undesired side chain oxidations play a role in the amyloid formation traits.
Representative m/z patterns of the distinct peptides after 80 h of incubation under aggregating conditions. Measurements were performed using samples of at least two separate experiments. Arrows indicate the theoretical positions for the m/z values of: 1) +1, 2) +16 (selenoxide), 3) +23 (Na+-adduct) and 4) +32 (selenone). For SeM35 the values are: 4376.1, 4381.1, 4388.1, 4408.1. For SeM analogs of HuPrP(106–140) the values are: 3377.2, 3393.2, 3399.2, 3409,2. The peak complexity arises from the Se isotopic distribution .
SeM containing sequences also function as exogenous fibrillation regulators
Consistent with the previous findings and with the fact that Met substitution by SeM would be hardly ever quantitative under physiological conditions, we next tested the capacity of the SeM-containing sequences to modulate the amyloid formation process of the unlabelled sequences. As amyloid formation can be essentially view as a seeded-polymerization in which nucleation, elongation and polymer fragmentation are critical steps, the SeM effects could also provide mechanistic information –. The results are shown in Figure 6.
(A) ThT binding kinetics of Aβ40 and Aβ42 in the absence (10 and 20 µM) and presence of [SeM35]Aβ40 (10 µM of each peptide). (B) Time evolution of the ThT binding of mixtures of 10 µM all-M HuPrP(106–126) in the absence and presence of 10 µM of HuPrP(106–126) sequence variants. (C) ThT binding kinetics of mixtures of 10 µM all-M HuPrP(106–126) in the absence and presence of 10 µM of HuPrP 106–126 sequence variants. The color code of the different traces is indicated at the right hand side of each panel. The displayed curves were obtained by continuous incubation of the different peptide solutions in PBS containing 15 µM ThT at 30°C in duplicate, and represent the average of three independent experiments.
Co-incubation of [SeM35]Aβ40 with Aβ40 and with its longer and more fibrillogenic form Aβ42 impaired their fibrillation process [Figure 6A]. These impairments could not be attributed to dilution since, in the absence of [SeM35]Aβ40 and at equal concentration, both Aβ40 and Aβ42 undergo fibrillation. Rather, the results agreed with an inhibition process and suggested that [SeM35]Aβ40 interacts with Met35-bearing peptides, and halts their productive aggregation through the formation of growth-impaired oligomers.
Similarly, in the HuPrP(106–140) case, co-incubation of 10 µM SeM129 analog with 10 µM of either all-M [Figure 6B] or all-V [Figure 6C] peptides inhibited amyloid formation. Again, such inhibitions could not be attributed to dilution effects, since the latter peptides, at 10 µM and in the absence of the SeM129 analog, yielded ThT binding kinetics compatible with fibrillation reactions. Hence, the inhibition trend suggests that [SeM129]HuPrP(106–140), acting like a quencher, interacts with either all-M or all-V HuPrP(106–140), giving rise to oligoheteromeric species that do not sustain growth. This data agreed with previous findings indicating the essential role of identity in position 129 for the allowance of formation of a stable steric zipper .
On the contrary, [SeM134]HuPrP(106–140), of very low efficiency in fibrillogenesis, when mixed with either all-M or all-V does not alter significantly the ThT binding pattern of the previous peptides [Figure 6B and 6C]. These results suggest that SeM134 precludes stable interaction and therefore causes its segregation. Since position 134 has not been found to play a fundamental role in amyloid formation, then the segregating behavior seems related to SeM hydrophobic properties and their provoked reactions , , .
On the other hand, SeM109 and SeM112 when mixed 1∶1 with either all-V or all-M peptides altered the ThT binding kinetics, imposing their characteristic lag-phase and allowing the final ThT intensity of the SeM-free peptide [Figure 6B and 6C]. This observation strongly suggests that positions 109 and 112 determine the efficiency of seed formation and therefore the speed of the polymerization reaction –.
SeM-containing sequences can ameliorate toxicity
To investigate the structure–activity relationship of the SeM substitutions we analyzed the effect of the aggregation reaction products on the viability of rodent primary cortical neurons [Figure 7]. For this purposes, the different peptides and their combination were incubated for 80 h at 30°C at 0.10–0.15 mM in PBS and then diluted to a final concentration of 10 µM in the cell medium and allowed to incubate for 48 h. Under the assay conditions, all peptides except [SeM35]Aβ40 and the SeM129 and SeM134-analogs of HuPrP(106–140) and their mixtures have completed their fibrillation process as judged by parallel ThT reading, and the untreated cells yielded cell viability values that amounted to 97.5±1%.
Rodent primary cortical neurons were cultured for 7 days on poly-D-lysine-coated coverslips and treated with 10 µM of each peptide or 1∶1 molar ratio mixture of peptides for 48 h. The cells were then probed with LIVE/DEAD kit. The percentage of dead cells was obtained dividing the number of dead cells by the total (live and dead) number of cells. The results are the means ± SD of three independent experiments ran in duplicate. Statistical analysis was performed with the Student's t test tool of Origin software. ns, non-significant. *, P<0.05; **, P<0.005.
Aβ40 was found to cause 11±1% cell death, in agreement with previous reports , , . Interestingly, [SeM35]Aβ40 reduced cell death to 3±1.5%, thereby excluding any relationship between its assemblies and the highly neurotoxic nonfibrillar oligomers formed by Aβ peptides . This reduction pattern was maintained for its 1∶1 mixture with Aβ40, which cannot be explained solely on the basis of [Met35]Aβ40 dilution as judged from the concentration control.
As for HuPrP(106–140), the aggregation reaction products of all-M and all-V caused about 20±2% of cell death, in agreement with the toxicity levels described for the polymers formed by HuPrP(82–146) . SeM109 and SeM112 analogs caused cell death to a similar extent, in agreement with their similar amyloid forming ability at long incubation times [Figure 3A]. On the contrary, SeM129 and to a lesser extent SeM134 caused minor effects on cell viability (1.1±0.5 and 4±0.6, respectively). As in the case of [SeM35]Aβ40, these statistically significant reductions in the extent of cell death compared to that caused by the amyloid-assembled sequences discards active oligomeric species. Moreover, the aggregation products of the all-M and all-V peptides mixed with SeM129 and SeM134 reproduced the profiles observed in kinetic experiments [Figure 6B and 6C]. Mixing SeM129 1∶1 with either all-M or all-V decreases cell death extent to almost abrogation, and the effect cannot be explained solely in terms of the reduction all-M and all-V concentration as shown by the concentration controls. On the contrary, mixing the SeM134 analog 1∶1 with either all-M or all-V reproduces the cell death percentage of diluted all-M and all-V peptides.
Unveiling the ways proamyloid sequences can be modulated to impede their productive engagement into self-assembly processes yielding toxic events is essential for designing preventing strategies for conformational diseases. The pioneer study of Goldschmidt et al  has solidly established as general principle that the capacity of a protein to form the β-sheet based fibrillar amyloid structures is coded in its sequence, although its display may depend on structural and environmental regulatory factors . One possible modulatory event is that involving metabolic changes of Met and SeM pools and consequently of their competitive incorporation in proteins through the AUG codon. Taking the advantage of synthetic approaches we have substituted Met by SeM in amyloid forming sequences and we have found dramatic effects on their polymerization and toxicity. These effects varied from inhibition ([SeM35]Aβ40 and [SeM129]PrP(106–140)), polymerization kinetics perturbation to polymer shape determination ([SeM112]PrP(106–140)) [Figure 8].
Replacement of methionine (M) residues by its metabolic competitor selenomethionine (SeM) in proamyloid sequences involves changes in local hydrophobicity and steric factors. With a site-dependence, the replacement can promote side association reaction that either decrease the efficiency and speed or impair amyloid formation. In other cases, by regulating the seed packing can generate distinct fibrilar assemblies.
Despite the consideration of Met and SeM as structurally equivalent, the change of a sulfur by a selenium atom involves major steric and reactivity differences. Se is slightly larger than S (atomic radius of 1.17 vs 1.04 Å) and has also a larger van der Waals radius (1.90 vs 1.80 Å).Since the spines of amyloid fibrils consist in steric zippers formed by the interdigitation of β-sheets through their side chains, any steric perturbation may lead to clashes which may reduce the stability of this unit or even preclude its formation , . This might be the case of the fibrillation impairments of [SeM35]Aβ40 and [SeM129]PrP(106–140) peptides, for which the crystal structure of shorter fragments have shown Met35 and Met129 actively participating in the inter-sheet packing , . Also, since the interdigitations are not unique but can involve distinct patterns, the side chain size increase together with its position can dictate the preference for specific stacking patterns over others that as seeds will produce distinct fibril shapes as for SeM109 and SeM112 analogs of PrP(106–140) , , . The larger size of Se than S also causes SeM to have a larger surface area and hence hydrophobicity than Met. Since amyloid formation is a complex process involving the construction of oligomeric species undergoing growth, fragmentation and quenching or arrest, minor changes in hydrophobicity may trigger significant alterations in the solubility of the distinct oligomeric species as well as in the the features of the interacting surfaces –, . For instance, by its increased hydrophobicity SeM can decrease the efficiency of amyloid formation in [SeM134]PrP(106–140), which retains the ability to engage in the process but does it with a very low efficiency.
SeM also differs from Met in its side chain oxidation process. SeM can undergo oxidation by peroxynitrites to selenoxide but, unlike the sulfoxide, the selenoxide is easily reduced by organic thiols as glutathione and does not required enzymatic assistance , , . Although SeM oxidation is not a major event in our experimental setup, since sulfoxide formation is known to impair fibrillation in Aβ40 and PrP(106–126), the chemical differences of the reaction could add novel regulatory steps to the polymerization –, , , . To address this possibility, improved basic knowledge is required on reaction conditions and product characterization of SeM oxidation as a part of a protein and free in solution , .
For Aβ40 the Met35SeM non-coded or metabolic mutation impairs amyloid formation but stabilizes oligomeric assemblies as shown by AFM. Based on shape considerations, the oligomers might be suspected to act as the actual neurotoxins. However, both PAGE-SDS analysis and toxicity evaluation discard such assemblies being deleterious and support the importance of the amyloid pathway as a source of toxic species. This rationale can be extended to the [SeM129]HuPrP(106–140) analog, which in addition to its impaired fibrillation and lack of toxic activity, prevents the fibrillation and toxicity of all-V and all-M. For these two cases, the incorporation of SeM into an essential position functions as a physiological anti-amyloid metabolic defense. However, the effect of SeM incorporation is not homogeneous. For instance, the SeM109 and SeM112 analogs of HuPrP(106–140) displayed differences in kinetics and in fibril shape, and such morphological differences can have important functional implications . In this sense, fibrils of the SeM112 –shape are expected to be more toxic that fibrils with shapes of the SeM109-analog, whereas if fragmented the toxicity profile inverts . In our set up, both assemblies yielded statistical similar toxicity traits suggesting that SeM substitution could also play a role in the in vivo stability (fragmentation or recycling) of the polymers so activity differences in the 48 h assay become averaged. In this line, H/D exchange experiments have shown that isolated fibrils can display significant distinct recycling properties, with changes in fibril dissolution rate constant of about two orders of magnitude ( 0.6 s−1 and 1.0×10−2 s−1 for Aβ40 and Aβ42, respectively) .
As summarized in Figure 8, these evidences clearly indicate that SeM incorporation into pro-amyloid sequences results in various effects as a function of its location and suggest that metabolic changes in the Met/SeM pool can exert important modulatory effects in amyloid diseases.
Materials and Methods
Peptides and aggregation reactions
The SeM-substituted versions of Aβ40 and HuPrP(106–140) (Figure 1A) were synthesized by solid phase methods, purified by HPLC and characterized by mass spectrometry. Details are given in the Supporting Information S1 file. For control studies, Aβ40 and Aβ42 were obtained from GenScript. Lyophilized peptide stocks were dissolved in HFIP, aliquoted and dried under N2 for storage at −80°C. Samples were reconstituted in 5 mM NH4OH pH 8.0 at about 2 mg/ml concentration and filtered through 0.2 µm membranes before use. Peptide concentrations were determined by UV spectroscopy and by amino acid analysis. Peptide stock solutions were diluted with PBS at 100–200 µM concentrations and kept at 4°C for less than 30 min. The aggregation reactions were performed both in eppendorf tubes and in wells of a 96-well plate by incubating 20–200 µM peptide monomers in PBS at 30°C with orbital shaking (100 rpm).
Thioflavin T binding kinetics
The kinetics of thioflavin T (ThT) binding was monitored by bottom reading of fluorescence intensity in a POLARstar microplate reader (BMG Labtech) as described . Measurements were performed using 450 nm excitation and 480 nm emission filters, 0.20 ml samples and 15 µM ThT concentration. The measurement program consisted of 10 flashes reading every 10 min with 1-min of orbital 1-mm diameter shaking at 100 rpm with the temperature controller set at 30°C. All measurements were done in triplicate and the experiments were repeated at least twice using two different peptide batches. When required, the lag-phase was determined as described .
Peptide samples before and after 80 h of aggregation were removed and diluted 1∶1 in β-mercaptoethanol-free Laemmli buffer and, omotting the thermal denaturation step, loaded in BioRad precastTGX-gels. After silver staining, gel images were captured and analyzed using the Molecular Imager ChemiDoc™ XRS+ Imaging system and ImageLab 3.0.1 (beta2) software (BioRad).
Mass spectrometry analysis
Aliquots of the peptide solutions before and after aggregation were removed, treated with HFIP for aggregate disruption and analyzed using α-hydroxy-cinnamic acid matrix and a MALDI FT-ICR 930-MS (Varian) instrument operating at 7 T and 10−9 Torr and with OMEGA software.
Atomic force microscopy (AFM)
Ten µl-samples of peptide solution after 70 h incubation were diluted to 2 µM with ddH2O and applied onto freshly cleaved mica surfaces to adhere for 15 min. After washing with ddH2O, samples were dried with N2. AFM imaging was then performed using a PicoSPM™ (Molecular Imaging, Phoenix, AZ), operating the AFM scanner in acoustic alternating current mode with Si,N-ACT type cantilevers (ScienTec) with a tip radius <10 nm and a spring constant of 25–75 N/m . The images (1×1 µm scans) were collected at a scan rate of 1 line per second and analyzed using WSxM 5.0 Nanotec software.
Circular dichroism (CD) spectroscopy
CD spectra were recorded in the far-UV region with a Jasco J-810 spectropolarimeter in continuous scan mode (250−190 nm) and a 0.1 cm path length quartz cuvette (Hellma) as described previously .
Mice were obtained from the Centro de Biología Molecular and treated following the guidelines of Council of Europe Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. Animal experiments were performed under protocols (P22/P23) approved by the Centro de Biología Molecular Severo Ochoa Institutional Animal Care and Utilization Committee (CEEA-CBM, Madrid, Spain). Primary cortical neurons were obtained from the cerebral cortex of C57B16 E18 rat embryos, by enzymatic dissociation with papain (Worthington Biochemical) in EBSS for 45 min at 37°C. Cells were resuspended in Neurobasal medium with 2% B27, 0.25% 200 mM Gln, 1% Glutamax and 1% penicillin/streptomycin and seeded on cover slips pre-coated with poly-D-Lys (10 µg/ml). Two days later, 5 µM Ara-C was added to the medium. Seven days later, peptides preincubated in PBS were added at a final concentration of 25 µM. After 48 h incubation at 37°C, neuronal cell death was determined using the LIVE/DEAD kit (Invitrogen) for mammalian cells. Live cells (stained with calcein-AM) and dead cells (stained with red-fluorescent ethidium homodimer-1) were counted and the percentage of dead cells calculated.
Angel Cuesta, Natalia Carulla, Juan Dávalos and Javier González are acknowledged for their advice on AFM and MALDI FT-ICR measurements.
Conceived and designed the experiments: MG JA DA EG. Performed the experiments: JM SL RS WK EZ MT MG. Analyzed the data: MG JM SL. Contributed reagents/materials/analysis tools: WK EZ MT EG DA JA. Wrote the paper: MG DA.
- 1. Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350: 134–138.RW CarrellDA Lomas1997Conformational disease.Lancet350134138
- 2. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678–699.M. StefaniCM Dobson2003Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.J Mol Med81678699
- 3. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333–366.F. ChitiCM Dobson2006Protein misfolding, functional amyloid, and human disease.Annu Rev Biochem75333366
- 4. Maji SK, Wang L, Greenwald J, Riek R (2009) Structure-activity relationship of amyloid fibrils. FEBS Lett 583: 2610–217.SK MajiL. WangJ. GreenwaldR. Riek2009Structure-activity relationship of amyloid fibrils.FEBS Lett5832610217
- 5. Goldschmidt L, Teng PK, Riek R, Eisenberg D (2010) Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A 107: 3487–3492.L. GoldschmidtPK TengR. RiekD. Eisenberg2010Identifying the amylome, proteins capable of forming amyloid-like fibrils.Proc Natl Acad Sci U S A10734873492
- 6. Toyama BH, Weissman JS (2010) Amyloid Structure: conformational diversity and consequences. Annu Rev Biochem 80: 557–585.BH ToyamaJS Weissman2010Amyloid Structure: conformational diversity and consequences.Annu Rev Biochem80557585
- 7. Shewmaker F, McGlinchey RP, Wickner RB (2011) Structural insights into functional and pathological amyloid. J Biol Chem 286: 16533–16540.F. ShewmakerRP McGlincheyRB Wickner2011Structural insights into functional and pathological amyloid.J Biol Chem2861653316540
- 8. Wiltzius JJ, Landau M, Nelson R, Sawaya MR, Apostol MI, et al. (2009) Molecular mechanisms for protein-encoded inheritance. Nat Struct Mol Biol 16: 973–978.JJ WiltziusM. LandauR. NelsonMR SawayaMI Apostol2009Molecular mechanisms for protein-encoded inheritance.Nat Struct Mol Biol16973978
- 9. Schrauzer GN (2000) Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr 130: 1653–1656.GN Schrauzer2000Selenomethionine: a review of its nutritional significance, metabolism and toxicity.J Nutr13016531656
- 10. Yokoyama S (2003) Protein expression systems for structural genomics and proteomics. Curr Opin Chem Biol 7: 39–43.S. Yokoyama2003Protein expression systems for structural genomics and proteomics.Curr Opin Chem Biol73943
- 11. Griffiths NM, Stewart RDH, Robinson MF (1976) The metabolism of (75Se)selenomethinine in four women. Br J Nutr 35: 373–382.NM GriffithsRDH StewartMF Robinson1976The metabolism of (75Se)selenomethinine in four women.Br J Nutr35373382
- 12. Rayman MP (2008) Food-chain selenium and human health: emphasis on intake. Br J Nutr 100: 254–268.MP Rayman2008Food-chain selenium and human health: emphasis on intake.Br J Nutr100254268
- 13. Méplan C (2011) Trace elements and ageing, a genomic perspective using selenium as an example. J Trace Elements Med Biol 255: 511–516.C. Méplan2011Trace elements and ageing, a genomic perspective using selenium as an example.J Trace Elements Med Biol255511516
- 14. McCann JC, Ames BN (2011) Adaptative dysfunction of selenoproteins from the perspective of the triage theory: why modest deficiency may increase risk of diseases of aging. FASEB J 25: 1793–1814.JC McCannBN Ames2011Adaptative dysfunction of selenoproteins from the perspective of the triage theory: why modest deficiency may increase risk of diseases of aging.FASEB J2517931814
- 15. Shahar A, Patel KV, Semba RD, Bandinelli S, Shahar DR, et al. (2010) Plasma selenium is positively related to performance in neurological tasks assessing coordination and motor speed. Mov Disord 25: 1909–1915.A. ShaharKV PatelRD SembaS. BandinelliDR Shahar2010Plasma selenium is positively related to performance in neurological tasks assessing coordination and motor speed.Mov Disord2519091915
- 16. Budisa N, Huber R, Golbik R, Minks C, Weyher E, et al. (1998) Atomic mutations in annexin V: thermodynamic studies of isomorphous protein variants. Eur J Biochem 253: 1–9.N. BudisaR. HuberR. GolbikC. MinksE. Weyher1998Atomic mutations in annexin V: thermodynamic studies of isomorphous protein variants.Eur J Biochem25319
- 17. Gassner NC, Baase WA, Hausrath AC, Matthews BW (1999) Substitution with selenomethionine can enhance the stability of methionine-rich proteins. J Mol Biol 294: 17–20.NC GassnerWA BaaseAC HausrathBW Matthews1999Substitution with selenomethionine can enhance the stability of methionine-rich proteins.J Mol Biol2941720
- 18. Håkansson K, Broder D, Wang AH, Miller CG (2000) Crystallization of peptidase T from Salmonella typhimurium. Acta Crystallogr D Biol Crystallogr 56: 924–926.K. HåkanssonD. BroderAH WangCG Miller2000Crystallization of peptidase T from Salmonella typhimurium.Acta Crystallogr D Biol Crystallogr56924926
- 19. Wernimont AK, Huffman DL, Finney LA, Demeler B, O'Halloran TV, et al. (2003) Crystal structure and dimerization equilibria of PcoC, a methionine-rich copper resistance protein from Escherichia coli. J Biol Inorg Chem 8: 185–194.AK WernimontDL HuffmanLA FinneyB. DemelerTV O'Halloran2003Crystal structure and dimerization equilibria of PcoC, a methionine-rich copper resistance protein from Escherichia coli.J Biol Inorg Chem8185194
- 20. Le DT, Liang X, Fomenko DE, Raza AS, Chong CK, et al. (2008) Analysis of methionine/selenomethionine oxidation and methionine sulfoxide reductase function using methionine-rich proteins and antibodies against their oxidized forms. Biochemistry 47: 6685–6694.DT LeX. LiangDE FomenkoAS RazaCK Chong2008Analysis of methionine/selenomethionine oxidation and methionine sulfoxide reductase function using methionine-rich proteins and antibodies against their oxidized forms.Biochemistry4766856694
- 21. Yamniuk AP, Ishida H, Lippert D, Vogel HJ (2009) Thermodynamic effects of noncoded and coded methionine substitutions in calmodulin. Biophys J 96: 1495–1507.AP YamniukH. IshidaD. LippertHJ Vogel2009Thermodynamic effects of noncoded and coded methionine substitutions in calmodulin.Biophys J9614951507
- 22. Collinge J, Palmer MS, Dryden AJ (1991) Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337: 1441–1442.J. CollingeMS PalmerAJ Dryden1991Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease.Lancet33714411442
- 23. Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, et al. (1996) Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A 93: 744–748.B. GhettiP. PiccardoMG SpillantiniY. IchimiyaM. Porro1996Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP.Proc Natl Acad Sci U S A93744748
- 24. Palmblad M, Westlind-Danielsson A, Bergquist J (2002) Oxidation of methionine 35 attenuates formation of amyloid β-peptide 1–40 oligomers. J Biol Chem 277: 19506–19510.M. PalmbladA. Westlind-DanielssonJ. Bergquist2002Oxidation of methionine 35 attenuates formation of amyloid β-peptide 1–40 oligomers.J Biol Chem2771950619510
- 25. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, et al. (2003) A molecular switch in amyloid assembly: Met35 and amyloid β-protein oligomerization. J Am Chem Soc 125: 15359–15365.G. BitanB. TarusSS VollersHA LashuelMM Condron2003A molecular switch in amyloid assembly: Met35 and amyloid β-protein oligomerization.J Am Chem Soc1251535915365
- 26. Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1–42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703: 149–156.DA ButterfieldD. Boyd-Kimball2005The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1–42)-induced oxidative stress and neurotoxicity.Biochim Biophys Acta1703149156
- 27. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101–112.C. HaassDJ Selkoe2007Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.Nat Rev Mol Cell Biol8101112
- 28. Green KM, Browning SR, Seward TS, Jewell JE, Ross DL, et al. (2008) The elk PRNP codon 132 polymorphism controls cervid and scrapie prion propagation. J Gen Virol 89: 598–608.KM GreenSR BrowningTS SewardJE JewellDL Ross2008The elk PRNP codon 132 polymorphism controls cervid and scrapie prion propagation.J Gen Virol89598608
- 29. Aguzzi A, Calella AM (2009) Prions: protein aggregation and infectious diseases. Physiol Rev 89: 1105–1152.A. AguzziAM Calella2009Prions: protein aggregation and infectious diseases.Physiol Rev8911051152
- 30. Haigh CL, Lewis VA, Vella LJ, Masters CL, Hill AF, et al. (2009) PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res 19: 1062–1078.CL HaighVA LewisLJ VellaCL MastersAF Hill2009PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site.Cell Res1910621078
- 31. Lee S, Antony L, Hartmann R, Knaus KJ, Surewicz K, et al. (2010) Conformational diversity in prion protein variants influences intermolecular beta-sheet formation. EMBO J 29: 251–262.S. LeeL. AntonyR. HartmannKJ KnausK. Surewicz2010Conformational diversity in prion protein variants influences intermolecular beta-sheet formation.EMBO J29251262
- 32. Parchi P, Strammiello R, Giese A, Kretzschmar H (2011) Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol 121: 91–112.P. ParchiR. StrammielloA. GieseH. Kretzschmar2011Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future.Acta Neuropathol12191112
- 33. Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, et al. (1994) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 91: 8378–8382.J. NäslundA. SchierhornU. HellmanL. LannfeltAD Roses1994Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging.Proc Natl Acad Sci USA9183788382
- 34. Butterfield DA, Bush AI (2004) Alzheimer's amyloid beta-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25: 563–568.DA ButterfieldAI Bush2004Alzheimer's amyloid beta-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide.Neurobiol Aging25563568
- 35. Clementi ME, Marini S, Coletta M, Orsini F, Giardina B, et al. (2005) Abeta(31–35) and Abeta(25–35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: Role of the redox state of methionine-35. FEBS Lett 579: 2913–2918.ME ClementiS. MariniM. ColettaF. OrsiniB. Giardina2005Abeta(31–35) and Abeta(25–35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: Role of the redox state of methionine-35.FEBS Lett57929132918
- 36. Johansson AS, Bergquist J, Volbracht C, Päiviö A, Leist M, et al. (2007) Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. Neuroreport 18: 559–563.AS JohanssonJ. BergquistC. VolbrachtA. PäiviöM. Leist2007Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation.Neuroreport18559563
- 37. Maiti P, Piacentini R, Ripoli C, Grassi C, Bitan G (2010) Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone. Biochem J 433: 323–332.P. MaitiR. PiacentiniC. RipoliC. GrassiG. Bitan2010Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone.Biochem J433323332
- 38. Gasset M, Baldwin MA, Lloyd DH, Gabriel JM, Holtzman DM, et al. (1992) Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A 89: 10940–10944.M. GassetMA BaldwinDH LloydJM GabrielDM Holtzman1992Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid.Proc Natl Acad Sci U S A891094010944
- 39. Salmona M, Morbin M, Massignan T, Colombo L, Mazzoleni G, et al. (2003) Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein. J Biol Chem 278: 48146–48153.M. SalmonaM. MorbinT. MassignanL. ColomboG. Mazzoleni2003Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein.J Biol Chem2784814648153
- 40. Petchanikow C, Saborio GP, Anderes L, Frossard MJ, Olmedo MI, et al. (2001) Biochemical and structural studies of the prion protein polymorphism. FEBS Lett 509: 451–456.C. PetchanikowGP SaborioL. AnderesMJ FrossardMI Olmedo2001Biochemical and structural studies of the prion protein polymorphism.FEBS Lett509451456
- 41. Dettin M, Pegoraro S, Rovero P, Bicciato S, Bagno A, et al. (1997) SPPS of difficult sequences. A comparison of chemical conditions, synthetic strategies and on-line monitoring. J Pept Res 49: 103–111.M. DettinS. PegoraroP. RoveroS. BicciatoA. Bagno1997SPPS of difficult sequences. A comparison of chemical conditions, synthetic strategies and on-line monitoring.J Pept Res49103111
- 42. Sohma Y, Hayashi Y, Kimura M, Chiyomori Y, Taniguchi A, et al. (2005) The ‘O-acyl isopeptide method’ for the synthesis of difficult sequence-containing peptides: application to the synthesis of Alzheimer's disease-related amyloid beta peptide (A-beta) 1–42. J Pept Sci 11: 441–451.Y. SohmaY. HayashiM. KimuraY. ChiyomoriA. Taniguchi2005The ‘O-acyl isopeptide method’ for the synthesis of difficult sequence-containing peptides: application to the synthesis of Alzheimer's disease-related amyloid beta peptide (A-beta) 1–42.J Pept Sci11441451
- 43. Garcia-Martin F, Quintanar-Audelo M, Garcia-Ramos Y, Cruz LJ, Gravel C, et al. (2006) ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides. J Comb Chem 8: 213–220.F. Garcia-MartinM. Quintanar-AudeloY. Garcia-RamosLJ CruzC. Gravel2006ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides.J Comb Chem8213220
- 44. Grillo-Bosch D, Rabanal F, Giralt E (2011) Improved Fmoc-based solid-phase synthesis of homologous peptides fragments of human and mouse prion proteins. J Pept Sci 17: 32–38.D. Grillo-BoschF. RabanalE. Giralt2011Improved Fmoc-based solid-phase synthesis of homologous peptides fragments of human and mouse prion proteins.J Pept Sci173238
- 45. LeVine H (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404–410.H. LeVine1993Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.Protein Sci2404410
- 46. Itkin A, Dupres V, Dufrêne YF, Bechinger B, Ruysschaert JM, et al. (2011) Calcium ions promote formation of amyloid β-peptide (1–40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One 6: e18250.A. ItkinV. DupresYF DufrêneB. BechingerJM Ruysschaert2011Calcium ions promote formation of amyloid β-peptide (1–40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease.PLoS One6e18250
- 47. Baskakov I, Disterer P, Breydo L, Shaw M, Gill A, et al. (2005) The presence of valine at residue 129 in human prion protein accelerates amyloid formation. FEBS Lett 579: 2589–2596.I. BaskakovP. DistererL. BreydoM. ShawA. Gill2005The presence of valine at residue 129 in human prion protein accelerates amyloid formation.FEBS Lett57925892596
- 48. Ostapchenko VG, Sawaya MR, Makarava N, Savtchenko R, Nilsson KP, et al. (2010) Two amyloid States of the prion protein display significantly different folding patterns. J Mol Biol 400: 908–921.VG OstapchenkoMR SawayaN. MakaravaR. SavtchenkoKP Nilsson2010Two amyloid States of the prion protein display significantly different folding patterns.J Mol Biol400908921
- 49. Makarava N, Ostapchenko VG, Savtchenko R, Baskakov IV (2009) Conformational switching within individual amyloid fibrils. J Biol Chem 284: 14386–14395.N. MakaravaVG OstapchenkoR. SavtchenkoIV Baskakov2009Conformational switching within individual amyloid fibrils.J Biol Chem2841438614395
- 50. Apostol MI, Sawaya MR, Cascio D, Eisenberg D (2010) Crystallographic studies of prion protein (PrP) segments suggest how structural changes encoded by polymorphism at residue 129 modulate susceptibility to human prion disease. J Biol Chem 285: 29671–29675.MI ApostolMR SawayaD. CascioD. Eisenberg2010Crystallographic studies of prion protein (PrP) segments suggest how structural changes encoded by polymorphism at residue 129 modulate susceptibility to human prion disease.J Biol Chem2852967129675
- 51. Lisa S, Meli M, Cabello G, Gabizon R, Colombo G, et al. (2010) The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci 67: 2825–2838.S. LisaM. MeliG. CabelloR. GabizonG. Colombo2010The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.Cell Mol Life Sci6728252838
- 52. Smith JL, Thompson A (1998) Reactivity of selenomethionine-dents in the magic bullet? Structure 6: 815–819.JL SmithA. Thompson1998Reactivity of selenomethionine-dents in the magic bullet?Structure6815819
- 53. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, et al. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046–32053.KN DahlgrenAM ManelliWB StineLK BakerGA Krafft2002Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.J Biol Chem2773204632053
- 54. Fioriti L, Angeretti N, Colombo L, De Luigi A, Colombo A, et al. (2007) Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein. J Neurosci 27: 1576–1583.L. FioritiN. AngerettiL. ColomboA. De LuigiA. Colombo2007Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein.J Neurosci2715761583
- 55. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103: 11045–50.ML DuennwaldS. JagadishPJ MuchowskiS. Lindquist2006Flanking sequences profoundly alter polyglutamine toxicity in yeast.Proc Natl Acad Sci U S A1031104550
- 56. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, et al. (2007) Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447: 453–457.MR SawayaS. SambashivanR. NelsonMI IvanovaSA Sievers2007Atomic structures of amyloid cross-β spines reveal varied steric zippers.Nature447453457
- 57. Krause RJ, Elfarra AA (2009) Reduction of L-methionine selenoxide to seleno-L-methionine by endogenous thiols, ascorbic acid, or methimazole. Biochem Pharmacol 77: 134–140.RJ KrauseAA Elfarra2009Reduction of L-methionine selenoxide to seleno-L-methionine by endogenous thiols, ascorbic acid, or methimazole.Biochem Pharmacol77134140
- 58. Bergström AL, Chabry J, Bastholm L, Heegaard PM (2007) Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106–126. Biochim Biophys Acta 1774: 1118–1127.AL BergströmJ. ChabryL. BastholmPM Heegaard2007Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106–126.Biochim Biophys Acta177411181127
- 59. Lee YJ, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV (2011) Molecular structure of amyloid fibrils controls the relationship between fibrillar size and toxicity. PLoS One 6: e20244.YJ LeeR. SavtchenkoVG OstapchenkoN. MakaravaIV Baskakov2011Molecular structure of amyloid fibrils controls the relationship between fibrillar size and toxicity.PLoS One6e20244
- 60. Sánchez L, Madurga S, Pukala T, Vilaseca M, López-Iglesias C, et al. (2011) Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties. J Am Chem Soc 133: 6505–6508.L. SánchezS. MadurgaT. PukalaM. VilasecaC. López-Iglesias2011Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties.J Am Chem Soc13365056508
- 61. Bishop MF, Ferrone FA (1984) Kinetics of nucleation-controlled polymerization. A perturbation treatment for use with a secondary pathway. Biophys J 46: 631–644.MF BishopFA Ferrone1984Kinetics of nucleation-controlled polymerization. A perturbation treatment for use with a secondary pathway.Biophys J46631644